AURA · Aura Biosciences Inc. Common Stock
View on chartInsiders & Stakes
| Natalie C. Holles See Remarks | ▲ Buy | Grant | 1,153,962 Shares held | 5/19/2026 | View profile |
| de los Pinos Elisabet See Remarks | ▲ Buy | Grant | 575,815 Shares held | 3/2/2026 | View profile |
| Janet Jill Hopkins Chief Medical Officer | ▲ Buy | Grant | 380,190 Shares held | 9/1/2026 | View profile |
| Anthony S. Gibney See Remarks | ▼ Sell | Open Market | 265,354 Shares held | 6/16/2026 | View profile |
| Mark Plavsic Chief Technical Officer | ▲ Buy | Grant | 243,736 Shares held | 3/2/2026 | View profile |
| Conor Kilroy General Counsel and Secretary | ▲ Buy | Grant | 232,693 Shares held | 7/1/2026 | View profile |
| David Michael Johnson Director | ▲ Buy | Grant | 194,167 Shares held | 6/11/2026 | View profile |
| Amy Elazzouzi SVP, Finance & PAO | ▲ Buy | Grant | 143,600 Shares held | 9/1/2026 | View profile |
| Abu-Absi Susan Chief Operating Officer | ▲ Buy | Grant | 134,513 Shares held | 9/1/2026 | View profile |
| Feder Julie B Chief Financial Officer | ▼ Sell | Open Market | 134,276 Shares held | 10/18/2024 | View profile |
| Person Julie Chief People Officer | ▲ Buy | Grant | 107,611 Shares held | 9/1/2026 | View profile |
| Kratz Erica Chief Reg. & Quality Officer | ▲ Buy | Grant | 100,885 Shares held | 9/1/2026 | View profile |
| Medicxi Ventures Management (Jersey) Ltd 10% Owner | ▲ Buy | Open Market | 70,540 Shares held | 11/2/2021 | View profile |
| Rich Cadmus See Remarks | ▲ Buy | Grant | 58,703 Shares held | 1/19/2023 | View profile |
| De Rosch Mark Chief Operating Officer | ▲ Buy | Grant | 58,635 Shares held | 1/19/2023 | View profile |
| Sapna Srivastava Director | ▲ Buy | Grant | 38,500 Shares held | 6/11/2026 | View profile |
| Antony C. Mattessich President and CEO | ▲ Buy | Grant | 38,500 Shares held | 6/11/2026 | View profile |
| Teresa Marie Bitetti President, OBU | ▲ Buy | Grant | 36,000 Shares held | 6/11/2026 | View profile |
| Jeremy Bender | ▲ Buy | Grant | 30,000 Shares held | 7/7/2026 | View profile |
| Primiano Christopher Brett Chief Business Officer | ▲ Buy | Grant | 8,750 Shares held | 10/28/2021 | View profile |
| Matrix Capital Management Company, LP 10% Owner | ▼ Sell | Open Market | 0 Shares held | 5/7/2026 | View profile |
Transaction History
| Janet Jill Hopkins | ▲ Buy | Grant | 58,850 | $0 | 9/1/2026 |
| Person Julie | ▲ Buy | Grant | 107,611 | $0 | 9/1/2026 |
| Kratz Erica | ▲ Buy | Grant | 100,885 | $0 | 9/1/2026 |
| Amy Elazzouzi | ▲ Buy | Grant | 23,540 | $0 | 9/1/2026 |
| Abu-Absi Susan | ▲ Buy | Grant | 134,513 | $0 | 9/1/2026 |
| Jeremy Bender | ▲ Buy | Grant | 30,000 | $0 | 7/7/2026 |
| Conor Kilroy | ▲ Buy | Grant | 14,858 | $0 | 7/1/2026 |
| Anthony S. Gibney | ▼ Sell | Open Market | 12,824 | $82K | 6/16/2026 |
| Teresa Marie Bitetti | ▲ Buy | Grant | 15,000 | $0 | 6/11/2026 |
| Sapna Srivastava | ▲ Buy | Grant | 15,000 | $0 | 6/11/2026 |
| David Michael Johnson | ▲ Buy | Grant | 15,000 | $0 | 6/11/2026 |
| Antony C. Mattessich | ▲ Buy | Grant | 15,000 | $0 | 6/11/2026 |
| Natalie C. Holles | ▲ Buy | Grant | 600,118 | $0 | 5/19/2026 |
| Natalie C. Holles | ▲ Buy | Grant | 553,844 | $0 | 5/19/2026 |
| Matrix Capital Management Company, LP | ▼ Sell | Open Market | 6,922,870 | $39.0M | 5/7/2026 |
| Conor Kilroy | ▼ Sell | Open Market | 11,738 | $82K | 4/16/2026 |
| Conor Kilroy | ▲ Buy | Grant | 62,339 | $0 | 3/2/2026 |
| Anthony S. Gibney | ▲ Buy | Grant | 71,245 | $0 | 3/2/2026 |
| de los Pinos Elisabet | ▲ Buy | Grant | 166,000 | $0 | 3/2/2026 |
| Mark Plavsic | ▲ Buy | Grant | 62,339 | $0 | 3/2/2026 |
| Janet Jill Hopkins | ▲ Buy | Grant | 89,056 | $0 | 3/2/2026 |
| Amy Elazzouzi | ▲ Buy | Grant | 44,528 | $0 | 3/2/2026 |
| Conor Kilroy | ▼ Sell | Open Market | 12,079 | $61K | 2/17/2026 |
| Mark Plavsic | ▼ Sell | Open Market | 15,890 | $80K | 2/17/2026 |
| Janet Jill Hopkins | ▼ Sell | Open Market | 20,401 | $103K | 2/17/2026 |
| Amy Elazzouzi | ▼ Sell | Open Market | 8,549 | $43K | 2/17/2026 |
| de los Pinos Elisabet | ▼ Sell | Open Market | 47,648 | $241K | 2/17/2026 |
| Amy Elazzouzi | ▼ Sell | Open Market | 1,581 | $8K | 1/20/2026 |
| de los Pinos Elisabet | ▼ Sell | Open Market | 16,928 | $82K | 1/20/2026 |
| Janet Jill Hopkins | ▼ Sell | Open Market | 17,109 | $93K | 11/17/2025 |
| Amy Elazzouzi | ▼ Sell | Open Market | 896 | $6K | 10/29/2025 |
| de los Pinos Elisabet | ▼ Sell | Open Market | 9,049 | $57K | 10/29/2025 |
| Mark Plavsic | ▼ Sell | Open Market | 12,169 | $77K | 10/16/2025 |
| Amy Elazzouzi | ▲ Buy | Option Exercise | 2,554 | $13K | 8/18/2025 |
| Amy Elazzouzi | ▲ Buy | Option Exercise | 1,094 | $6K | 8/18/2025 |
| Amy Elazzouzi | ▲ Buy | Option Exercise | 547 | $3K | 8/18/2025 |
| Amy Elazzouzi | ▲ Buy | Option Exercise | 547 | $3K | 8/18/2025 |
| Amy Elazzouzi | ▲ Buy | Option Exercise | 4,744 | $13K | 8/18/2025 |
| Amy Elazzouzi | ▲ Buy | Option Exercise | 1,094 | $3K | 8/18/2025 |
| Amy Elazzouzi | ▲ Buy | Option Exercise | 2,319 | $10K | 8/18/2025 |
| Amy Elazzouzi | ▼ Sell | Open Market | 7,722 | $52K | 8/18/2025 |
| Sapna Srivastava | ▲ Buy | Grant | 13,000 | $0 | 6/17/2025 |
| David Michael Johnson | ▲ Buy | Grant | 13,000 | $0 | 6/17/2025 |
| Antony C. Mattessich | ▲ Buy | Grant | 13,000 | $0 | 6/17/2025 |
| Anthony S. Gibney | ▲ Buy | Grant | 150,000 | $0 | 6/2/2025 |
| de los Pinos Elisabet | ▲ Buy | Option Exercise | 10,948 | $56K | 6/2/2025 |
| de los Pinos Elisabet | ▼ Sell | Tax Withholding | 9,948 | $61K | 6/2/2025 |
| David Michael Johnson | ▲ Buy | Open Market | 20,000 | $98K | 5/16/2025 |
| Anthony S. Gibney | ▲ Buy | Open Market | 50,000 | $245K | 5/16/2025 |
| Anthony S. Gibney | ▼ Sell | Open Market | 1,519 | $8K | 5/16/2025 |
| Amy Elazzouzi | ▼ Sell | Open Market | 897 | $5K | 4/16/2025 |
| Conor Kilroy | ▼ Sell | Open Market | 7,162 | $39K | 4/16/2025 |
| Teresa Marie Bitetti | ▲ Buy | Grant | 21,000 | $0 | 3/31/2025 |
| Mark Plavsic | ▼ Sell | Open Market | 2,151 | $17K | 2/18/2025 |
| Amy Elazzouzi | ▼ Sell | Open Market | 1,404 | $11K | 2/18/2025 |
| Janet Jill Hopkins | ▼ Sell | Open Market | 2,534 | $20K | 2/18/2025 |
| de los Pinos Elisabet | ▼ Sell | Open Market | 20,221 | $157K | 2/18/2025 |
| Amy Elazzouzi | ▲ Buy | Grant | 45,240 | $0 | 2/3/2025 |
| Conor Kilroy | ▲ Buy | Grant | 90,475 | $0 | 2/3/2025 |
| Janet Jill Hopkins | ▲ Buy | Grant | 120,635 | $0 | 2/3/2025 |
| Mark Plavsic | ▲ Buy | Grant | 90,475 | $0 | 2/3/2025 |
| de los Pinos Elisabet | ▲ Buy | Grant | 194,320 | $0 | 2/3/2025 |
| de los Pinos Elisabet | ▼ Sell | Open Market | 15,955 | $122K | 1/21/2025 |
| Amy Elazzouzi | ▼ Sell | Open Market | 1,001 | $8K | 1/21/2025 |
| Janet Jill Hopkins | ▼ Sell | Open Market | 11,822 | $111K | 11/18/2024 |
| de los Pinos Elisabet | ▼ Sell | Open Market | 9,200 | $99K | 10/29/2024 |
| Amy Elazzouzi | ▼ Sell | Open Market | 553 | $6K | 10/29/2024 |
| Feder Julie B | ▲ Buy | Option Exercise | 17,500 | $48K | 10/18/2024 |
| Feder Julie B | ▲ Buy | Option Exercise | 2,631 | $11K | 10/18/2024 |
| Feder Julie B | ▲ Buy | Option Exercise | 5,000 | $27K | 10/18/2024 |
| Feder Julie B | ▼ Sell | Open Market | 25,131 | $302K | 10/18/2024 |
| de los Pinos Elisabet | ▲ Buy | Option Exercise | 24,992 | $68K | 10/18/2024 |
| de los Pinos Elisabet | ▼ Sell | Open Market | 24,992 | $301K | 10/18/2024 |
| Mark Plavsic | ▼ Sell | Open Market | 7,383 | $73K | 10/16/2024 |
| de los Pinos Elisabet | ▲ Buy | Option Exercise | 5,474 | $32K | 9/27/2024 |
| David Michael Johnson | ▲ Buy | Grant | 10,500 | $0 | 6/20/2024 |
| Antony C. Mattessich | ▲ Buy | Grant | 10,500 | $0 | 6/20/2024 |
| Sapna Srivastava | ▲ Buy | Grant | 10,500 | $0 | 6/20/2024 |
| Conor Kilroy | ▲ Buy | Grant | 96,000 | $0 | 4/2/2024 |
| Janet Jill Hopkins | ▲ Buy | Grant | 28,515 | $0 | 2/1/2024 |
| Feder Julie B | ▲ Buy | Grant | 71,285 | $0 | 2/1/2024 |
| de los Pinos Elisabet | ▲ Buy | Grant | 162,935 | $0 | 2/1/2024 |
| de los Pinos Elisabet | ▼ Sell | Open Market | 15,853 | $121K | 1/23/2024 |
| Feder Julie B | ▼ Sell | Open Market | 6,609 | $51K | 1/23/2024 |
| Matrix Capital Management Company, LP | ▲ Buy | Open Market | 1,560,000 | $14.0M | 11/9/2023 |
| David Michael Johnson | ▲ Buy | Open Market | 9,601 | $70K | 11/8/2023 |
| David Michael Johnson | ▲ Buy | Open Market | 10,000 | $73K | 11/8/2023 |
| David Michael Johnson | ▲ Buy | Open Market | 10,000 | $73K | 11/8/2023 |
| David Michael Johnson | ▲ Buy | Open Market | 76,000 | $545K | 11/7/2023 |
| David Michael Johnson | ▲ Buy | Open Market | 47,000 | $337K | 11/7/2023 |
| David Michael Johnson | ▲ Buy | Open Market | 47,000 | $337K | 11/7/2023 |
| de los Pinos Elisabet | ▲ Buy | Option Exercise | 3,800 | $10K | 11/6/2023 |
| de los Pinos Elisabet | ▼ Sell | Open Market | 7,449 | $90K | 11/6/2023 |
| Feder Julie B | ▲ Buy | Option Exercise | 3,900 | $11K | 11/6/2023 |
| Feder Julie B | ▼ Sell | Open Market | 3,900 | $47K | 11/6/2023 |
| Janet Jill Hopkins | ▲ Buy | Grant | 135,000 | $0 | 11/1/2023 |
| Feder Julie B | ▼ Sell | Open Market | 3,385 | $23K | 10/30/2023 |
| de los Pinos Elisabet | ▼ Sell | Open Market | 9,586 | $65K | 10/30/2023 |
| David Michael Johnson | ▲ Buy | Open Market | 6,566 | $57K | 10/4/2023 |
| David Michael Johnson | ▲ Buy | Open Market | 13,500 | $112K | 10/3/2023 |
| de los Pinos Elisabet | ▲ Buy | Grant | 121,875 | $0 | 1/19/2023 |
| De Rosch Mark | ▲ Buy | Grant | 42,250 | $0 | 1/19/2023 |
| Feder Julie B | ▲ Buy | Grant | 48,750 | $0 | 1/19/2023 |
| Rich Cadmus | ▲ Buy | Grant | 34,125 | $0 | 1/19/2023 |
| David Michael Johnson | ▲ Buy | Open Market | 700 | $7K | 1/6/2023 |
| David Michael Johnson | ▲ Buy | Open Market | 904 | $10K | 1/6/2023 |
| David Michael Johnson | ▲ Buy | Open Market | 96 | $960 | 1/5/2023 |
| David Michael Johnson | ▲ Buy | Open Market | 300 | $3K | 1/5/2023 |
| David Michael Johnson | ▲ Buy | Open Market | 2,000 | $20K | 12/28/2022 |
| David Michael Johnson | ▲ Buy | Open Market | 2,000 | $20K | 12/28/2022 |
| Matrix Capital Management Company, LP | ▲ Buy | Open Market | 1,250,000 | $15.0M | 12/5/2022 |
| David Michael Johnson | ▲ Buy | Open Market | 5,000 | $62K | 12/1/2022 |
| David Michael Johnson | ▲ Buy | Open Market | 5,000 | $62K | 12/1/2022 |
| Feder Julie B | ▼ Sell | Open Market | 2,015 | $25K | 10/31/2022 |
| de los Pinos Elisabet | ▼ Sell | Open Market | 5,706 | $71K | 10/31/2022 |
| De Rosch Mark | ▼ Sell | Open Market | 1,115 | $14K | 10/31/2022 |
| Rich Cadmus | ▼ Sell | Open Market | 1,672 | $21K | 10/31/2022 |
| David Michael Johnson | ▲ Buy | Open Market | 7,000 | $98K | 6/13/2022 |
| David Michael Johnson | ▲ Buy | Open Market | 7,000 | $98K | 6/13/2022 |
| David Michael Johnson | ▲ Buy | Open Market | 20,000 | $280K | 6/13/2022 |
| David Michael Johnson | ▲ Buy | Open Market | 3,000 | $45K | 6/10/2022 |
| David Michael Johnson | ▲ Buy | Open Market | 3,000 | $45K | 6/10/2022 |
| David Michael Johnson | ▲ Buy | Open Market | 10,000 | $150K | 6/10/2022 |
| Medicxi Ventures Management (Jersey) Ltd | ▲ Buy | Open Market | 693,525 | $9.7M | 11/2/2021 |
| Medicxi Ventures Management (Jersey) Ltd | ▲ Buy | Open Market | 16,475 | $231K | 11/2/2021 |
| Matrix Capital Management Company, LP | ▼ Sell | Other | 2,327,870 | — | 11/2/2021 |
| Matrix Capital Management Company, LP | ▲ Buy | Open Market | 1,785,000 | $25.0M | 11/2/2021 |
| de los Pinos Elisabet | ▼ Sell | Other | 4,552 | $0 | 11/2/2021 |
| David Michael Johnson | ▼ Sell | Other | 139,672 | $0 | 11/2/2021 |
| Medicxi Ventures Management (Jersey) Ltd | ▼ Sell | Other | 54,065 | — | 11/2/2021 |
| Medicxi Ventures Management (Jersey) Ltd | ▼ Sell | Other | 2,275,827 | — | 11/2/2021 |
| Rich Cadmus | ▲ Buy | Grant | 26,250 | $0 | 10/28/2021 |
| de los Pinos Elisabet | ▲ Buy | Grant | 74,357 | $0 | 10/28/2021 |
| De Rosch Mark | ▲ Buy | Grant | 17,500 | $0 | 10/28/2021 |
| Feder Julie B | ▲ Buy | Grant | 26,250 | $0 | 10/28/2021 |
| Primiano Christopher Brett | ▲ Buy | Grant | 8,750 | $0 | 10/28/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Aura Biosciences Announces Conference Participation and Inducement Grants
Aura Biosciences announced plans to participate in an upcoming investor conference, a routine event that gives the company an opportunity to engage with shareholders and potential investors. Separately, the company disclosed standard inducement equity grants made to new employees under Nasdaq listing rules, a required disclosure when companies use equity compensation to attract talent. Neither announcement contains material non-public information or forward-looking guidance. The stock is currently trading near its 52-week range midpoint with a neutral RSI reading.
Aura Biosciences Announces Conference Participation and Inducement Grants. Aura Biosciences announced plans to participate in an upcoming investor conference, a routine event that gives the company an opportunity to engage with shareholders and potential investors. Separately, the company disclosed standard inducement equity grants made to new employees under Nasdaq listing rules, a required disclosure when companies use equity compensation to attract talent. Neither announcement contains material non-public information or forward-looking guidance. The stock is currently trading near its 52-week range midpoint with a neutral RSI reading.